Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan 15;68(2):143-50.
doi: 10.2146/ajhp100113.

Development and implementation of a pharmacist-managed clinical pharmacogenetics service

Kristine R Crews  1 , Shane J Cross, John N McCormick, Donald K Baker, Alejandro R Molinelli, Richard Mullins, Mary V Relling, James M Hoffman
Affiliations

Development and implementation of a pharmacist-managed clinical pharmacogenetics service

Kristine R Crews et al. Am J Health Syst Pharm. .

Abstract

Purpose: The development and implementation of a pharmacist-managed clinical pharmacogenetics service are described.

Summary: A pharmacist-managed clinical pharmacogenetics service was designed and implemented at an academic specialty hospital to provide clinical pharmacogenetic testing for gene products important to the pharmacodynamics of medications used in the hospital's patients. A series of accredited educational seminars were conducted for our pharmacists to establish competencies in providing pharmacogenetic consults for the genes to be tested by the clinical pharmacogenetics service. The service was modeled after and integrated with an already-established clinical pharmacokinetics service. A steering committee was formed to evaluate the use of available tests, new evidence for implementation of additional tests, and other service quality metrics. All clinical pharmacogenetic test results are first reported to one of the pharmacists, who reviews the result and provides a written consultation. The consultation includes an interpretation of the result and recommendations for any indicated changes to therapy. In 2009, 136 clinical pharmacogenetic tests were performed. The service has been met with positive clinician feedback. The successful implementation of this service highlights the leadership role that pharmacists can take in moving pharmacogenetics from research to patient care.

Conclusion: The development of and experience with a pharmacist-managed clinical pharmacogenetics service are described. The program's success has depended on collaboration between the clinical laboratory and pharmacists, and pharmacists' pharmacogenetic recommendations have been well accepted by prescribers.

PubMed Disclaimer

Conflict of interest statement

The authors have declared no potential conflicts of interest.

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

References

    1. Radomski KM, Bush BA, Ensom MH. Collaboration between pharmacy and laboratory: defining total allowable error limits for therapeutically monitored drugs. Annals of Pharmacotherapy. 1998;32:170–175. - PubMed
    1. Streetman DS, Nafziger AN, Destache CJ, Bertino AS., Jr Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001;21:443–451. - PubMed
    1. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health Syst Pharm. 2005;62:1596–1605. - PubMed
    1. Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL. Evidence of the economic benefit of clinical pharmacy services: 1996–2000. Pharmacotherapy. 2003;23:113–132. - PubMed
    1. American Society of Health-System Pharmacists. ASHP statement on the pharmacist's role in clinical pharmacokinetic monitoring. Am J Health-Syst Pharm. 1998;55:1726–1727. - PubMed

Publication types

MeSH terms